LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study-Reference-Cited by-同舟云学术

LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study

Published:2021-09 Issue: Volume:32 Page:S1316-S1317
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Ascierto P.A.,Mandala M.,Ferrucci P.F.,Rutkowski P.,Guidoboni M.,Arance Fernandez A.M.,Ferraresi V.,Maiello E.,Guida M.,Del Vecchio M.,Fierro M.T.,Queirolo P.,Lebbe C.,Helgadottir H.,Melero I.,Palmieri G.,Giannarelli D.,Grimaldi A.M.,Dummer R.,Chiarion Sileni V.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States;Melanoma Research;2024-07-16

2. The outcome in patients with BRAF‐mutated metastatic melanoma treated with anti‐programmed death receptor‐1 monotherapy or targeted therapy in the real‐world setting;Cancer Medicine;2024-03

3. Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center’s decade of experience;Frontiers in Oncology;2024-02-21

4. Long-term preservation of the effect of immunotherapy with pembrolizumab as a second line treatment for recurrent skin melanoma;Meditsinskiy sovet = Medical Council;2024-01-17

5. Real‐world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy;Pharmacoepidemiology and Drug Safety;2023-04-24